01830nas a2200349   4500000000100000008004100001260001300042653001000055653001200065653003000077653002500107653002800132653001100160653001100171653002400182653002900206653002800235653001200263653000900275100001100284700001100295700001100306700001300317700001200330245012000342856005900462300001000521490000700531050003200538520089600570022001401466       1995                            d  c1995 Sep10aAdult10aAnimals10aAntimony Sodium Gluconate10aAntiprotozoal Agents10aDiagnosis, Differential10aFemale10aHumans10aLeishmania donovani10aLeishmaniasis, Cutaneous10aLeishmaniasis, Visceral10aleprosy10aMale1 aDhar S1 aKaur I1 aDawn G1 aSehgal S1 aKumar B00aPost-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.  uhttp://leprev.ilsl.br/pdfs/1995/v66n3/pdf/v66n3a10.pdf  a250-60 v66  aInfolep Library - available3 a<p>We report on 4 cases of post-kala-azar dermal leishmaniasis (PKDL). History of kala-azar was available in all 4 patients. Slit-skin smears (SSS) for leishmania donovani (LD) bodies were negative in all 4. In 3 patients hypopigmented lesions were present over the face. Papules and nodules over his lips, tongue, scrotum and dactylitis were some unusual features observed in 1 patient. Histopathological examination showed LD bodies in 2 patients; histopathology was nonspecific in the other 2. All the patients were treated with sodium stibogluconate, 20 mg/kg/day. Infiltrated papules and nodules had subsided by 3 months, while hypopigmented macules took longer to improve. In 3 patients there had previously been a misdiagnosis as leprosy sufferers and they had been treated with antileprosy drugs. Clinical and histopathological differences between PKDL and leprosy are discussed.</p>  a0305-7518